Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies

Epidermal Growth Factor Receptor cooperates with Src Family Kinases in acquired resistance to cetuximab

(2010) Deric L. Wheeler et al.   CANCER BIOLOGY & THERAPY

Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Non–Small-Cell Lung Cancer

(2010) Eric B. Haura et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Dasatinib in Patients With Advanced Non–Small-Cell Lung Cancer

(2010) Faye M. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

A chemical and phosphoproteomic characterization of dasatinib action in lung cancer

(2010) Jiannong Li et al.   Nature Chemical Biology

Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up

(2009) H. Kantarjian et al.   BLOOD

Dose-Dependent Increases in Circulating TGF-  and Other EGFR Ligands Act As Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent

(2009) A. J. Mutsaers et al.   CLINICAL CANCER RESEARCH

Src Promotes Survival and Invasion of Lung Cancers with Epidermal Growth Factor Receptor Abnormalities and Is a Potential Candidate for Molecular-Targeted Therapy

(2009) E. L.-H. Leung et al.   MOLECULAR CANCER RESEARCH

Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma: Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors

(2009) Ann Marie Egloff et al.   Journal of Oncology

Combined Inhibition of c-Src and Epidermal Growth Factor Receptor Abrogates Growth and Invasion of Head and Neck Squamous Cell Carcinoma

(2008) P. Koppikar et al.   CLINICAL CANCER RESEARCH